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osting by EAbstract Background: Determine the incidence of four thiopurine S-methyltransferase (TPMT)
mutant alleles, TPMT*2, *3A, *3B and *3C in the Tunisian population involved in adverse drug
reactions.
Genomic DNAs were isolated from peripheral blood leucocytes of 119 healthy Tunisian volun-
teers. The frequencies of four allelic variants of the TPMT gene, TPMT*2, *3A, *3B, *3C were
determined using allele speciﬁc polymerase chain reaction (PCR) or PCR-restriction fragment
length polymorphism technique.
Results: Of the 119 Tunisian subjects participating in this study, 117 subjects (98.3%) were
homozygous for TPMT*1 and only two subjects (1.68%) were heterozygous for TPMT*1/*3A.
The frequency of TPMT*3A mutant allele was 0.009.
Conclusions: Our study provides the ﬁrst data on the frequency of common TPMT variants in
the Tunisian population. TPMT*3A, which causes the largest decrease in enzyme activity, seemed
to be a unique variant allele found in this our population.
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lsevier1. Introduction
Thiopurine S-methyltransferase (TPMT) is a very important
cytoplasmic transmethylase enzyme that preferentially cata-
lyzes S-methylation of thiopurine drugs, activating or detoxify-
ing the immunosuppressant azathioprine and the anticancer
agents, 6-mercaptopurine and 6-thioguanine [1]. These thiopu-
rine drugs are used in the treatment of inﬂammatory diseases,
such as ulcerative colitis, dermatitis, and rheumatoid arthritis,
and following organ transplantation. TPMT was shown to be
present in most tissues, e.g., blood cells, heart, pancreas, pla-
centa, and intestine [2].
Table 1 Observed and expected genotype frequencies of
TPMT in Tunisian subjects.
TPMT tested gene N % Observed frequency (95% CI)
*1/*1 117 98.32 (94.06–99.79)
*1/*2 0 0
*1/*3A 2 1.68 (0.2–5.93)
*1/*3B 0 0
*1/*3C 0 0
Observed genotype frequency was expressed in percentage with
95% conﬁdence interval (CI) shown in brackets.
184 L. Ben Salah et al.The activity of the human TPMT varies greatly between
individuals because of genetic polymorphism. TPMT activity
is inherited as an autosomal codominant trait and was shown
to be highly variable, with 90% of individuals having high/nor-
mal activity, 10% with intermediate activity and 0.3% with
low/absent activity [3]. The TPMT gene variant was originally
described in 1980 [4]. To date, more than 20 variant alleles
associated with reduced enzymatic activity have been reported
[5].
The prevalent alleles that have been associated with low or
absent enzyme activity, are TPMT*2 (G238C), TPMT*3A
(G460A and A719G), TPMT*3B (only G460A) and TPMT*3C
(only A719G).TPMT deﬁciency is associated with severe hema-
topoietic toxicity when conventional dosages of thiopurine
drugs are used. In a recent meta-analysis Higgs et al. suggests
that individuals with both intermediate and absentTPMT activ-
ity have an increased risk of developing thiopurine-induced
myelosuppression, compared with individuals with normal
activity [6].
The greatest risk of hematopoietic toxicity seems to be asso-
ciated with homozygous TPMT variants while; patients with
heterozygous TPMT genotypes are at intermediate risk [2,7,8].
However, TPMT-deﬁcient patients can be successfully treated
with reduced dosages of thiopurines [9,10]. Therefore, the level
of TPMT enzyme activity is essential to prevent thiopurine tox-
icity and to optimize therapeutic drug treatment. The identiﬁca-
tion and frequencies distributions of variant TPMT alleles have
been reported inmany ethnic groups but there is no study on the
TPMT polymorphism in Tunisians population.
The aim of this study is to characterize the most common
TPMT alleles in the Tunisian population.
2. Material and methods
Hundred and nineteen Tunisian volunteers (67 females, 52
males, aged 35.4 ± 10.7 years) were included in this study.
Subjects were healthy as deﬁned by medical history and phys-
ical examination.
Informed written consent was obtained from all the subjects
and the protocol was accepted by the Ethical Committee of the
university Hospital (CHU) Sahloul of Sousse(Tunisia).
Genomic DNA was isolated from blood samples using the
Wizard Genomic DNA Puriﬁcation Kit (cat. # A1120) (Pro-
mega. Madison, USA) according to the instructions of the
manufacturer.
The genotypes of each individual at the principal TPMT
mutations G238C (TPMT*2), G460A and A719G (TPMT*3A),
G460A (TPMT*3B) and A719G (TPMT*3C) were determined
using previously described Polymerase Chain Reaction
(PCR)-based assays with minor modiﬁcation. An allele-speciﬁc
PCRmethodwas used to analyze theG238Cmutation in exon 5,
while PCR ampliﬁcation and restriction enzyme digestion were
used to detect the G460A and A719G mutation, respectively.
The resultant PCR products of exon 7 and 10 were digested with
restriction enzymeMwol and AccI (New England Biolabs, Hert-
fordshire, UK), respectively.
The PCR reactions were performed in a volume of 25 ll
with 30 cycles denaturation for TPMT*3C and TPMT*3B
and 29 cycles for TPMT*2. PCR was carried out using
100 ng of DNA in a ﬁnal volume 25 ll, with 25 mM dNTP,
10 lM of each primer, 25 mM MgCl2 Boehringer and 0.1 ll
of Taq polymerase 5 U/ll (Boehringer Mannheim GmbH).PCR ampliﬁcation consisted of an initial denaturation step
at 94 C for 1 min followed by 29 cycles or 30 cycles of dena-
turation at 94 C for 2 min, annealing at 60 C (TPMT*2) or
58 C (TPMT*3C and TPMT*3B) and extension at 72 C for
1.5 min. The ﬁnal extension step was performed at 72 C for
7 min.
The statistical signiﬁcance in allele or genotype frequency
between different populations was evaluated using a Chi-
square test or v2 test.
3. Results and discussion
The results of the genotype analysis are summarized in Table
1. A total of 117 subjects (98.32%; 95% CI 94.06–99.79) was
homozygous for the wild-type allele (TPMT*1), i.e. they did
not carry any of the tested mutations. Two subjects (1.68%;
95% CI 0.2–5.93) were heterozygous for TPMT*1/*3A giving
allele frequencies of 0.009.
The genotype analysis of the Tunisian population revealed
that the frequency of total TPMT variant alleles was low
(1.6%). The low overall frequency of variant alleles in this
study may be due to limited size of the population studied
(238 alleles) and could be due to the peculiarity of the Tunisian
population. The TPMT*3A, which causes the largest decrease
in enzyme activity, is the only variant allele detected in this
Tunisian population.
The frequency of this variant found in the present study
(0.009) is similar (P> 0.05) to the frequency reported for
Egyptians [11] and South West Asians [12], but signiﬁcantly
lower than the frequencies reported for Caucasian popula-
tions, including Americans [13], British [14], French [14], Ital-
ians [15], and Polish [16] (Table 2). It is also lower than the
frequencies reported for Latin-Americans populations [17–
20] (Table 2). TPMT*3A is the most prevalent nonfunctional
variant allele of TPMT in Caucasians, Latin-Americans and
Turkishs populations [27–28]. Subjects with heterozygous
genotype *1/*3A have one active TPMT allele, and their risk
of thiopurine hematopoietic toxicity is greater than that of pa-
tients who have a homozygous wild-type TPMT genotype
(35% versus 7%), but not as great a risk as those who have
2 nonfunctional TPMT alleles (100%) [21]. TPMT*3A has
not been detected in most of the Asian populations [22–25].
TPMT*3C was detected in all Africans except our Tunisian
population (Table 2). In Africans such as Egyptians, this
mutant allele represents 86% of the TPMT variant allele
[12]. TPMT*3C accounts also for 100% in the Chinese, Japa-
nese and Ghanaian [12,22,26], 70% of African-Americans [13],
5% of Caucasians [14] while it has not been detected in Argen-
tinean and Colombian populations [17,18].The results from the
Table 2 Comparative allele frequencies of thiopurine S-methyltransferase in Tunisian compared with populations reported in other
studies.
Populations Allele frequency
N *1 *2 *3A *3C
Africans
Tunisian (Present study) 238 0.991 0 0.009 0
Kenyan [14] 202 0.946** 0 0 0.054**
Ghanaian [26] 434 0.924** 0 0 0.076**
Egyptian [11] 400 0.985 0 0.003 0.013
Asians
Japanese [22] 1044 0.984 0 0 0.016
Japanese [23] 142 0.979 0 0 0.014
Thai [22] 400 0.950** 0 0 0.050**
Chinese [14] 384 0.97 0 0 0.023*
Taiwanese [25] 498 0.994 0 0 0.006
South-West [12] 198 0.99 0 0.01 0
Caucasians
American [13] 564 0.964* 0.002 0.032* 0.002
British [14] 398 0.947** 0.005 0.045* 0.003
French [14] 382 0.93** 0.005 0.057** 0.008
Italian [15] 412 0.946** 0.005 0.039* 0.010
Polish [16] 716 0.939** 0.008 0.05** 0.003
Latin-Americans
Argentinean [17] 294 0.972 0.007 0.021 0
Colombian [18] 280 0.96* 0.004 0.036* 0
Chilean [19] 420 0.9619* 0.0024 0.0286 0.0071
Brazilian [20] 408 0.951** 0.022 0.015 0.01
Turkish [27] 212 0.981 0 0.0094 0.0094
Turkish [28] 116 0.914 0 0.034 0.009
N: number of alleles detected. Signiﬁcant differences from Tunisian population:
* P< 0.05.
** P< 0.005.
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frequency in the Tunisian population is similar to those deter-
mined for South West Asians populations including people
from India, Pakistan, Sri Lanka and Nepal [12]. The variants
allele TPMT*2 and TPMT*3B have also not been detected in
these populations. TPMT*2 and TPMT*3B were not detected
among 238 studied alleles suggesting that it may be absent or
rare in Tunisian population.
4. Conclusions
To our knowledge, the current study is the ﬁrst one that pre-
sents data for TPMT polymorphisms in Tunisian population.
The results from the present study revealed that TPMT*3A,
variant enzyme with negligible activity compared to the wild
type, was the only mutant allele among the Tunisian popula-
tion of this study, suggesting that among Tunisians patients
treated by thiopurine drugs a risk of severe hematopoietic tox-
icity is present. Several previous studies have shown that low
TPMT activity is associated with bone marrow toxicity and
adverse drug reactions but the efﬁcacy of the strategy of
screening the TPMT gene mutation in all patients prior to ini-
tiating treatment with thiopurine drugs is a matter of debate.
This study support the assessment of TPMT genotype prior
to thiopurine drugs therapy as a supplement to other routine
and still essential measure for ensuring safe thiopurine drugs
use, including monitoring of blood cell counts.Competing interests
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